Prelude Therapeutics Incorporated (PRLD) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts PRLD Hot Sheet
Join SI Premium – FREE
Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q3 EPS of ($0.43), $0.04 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $3 million versus the consensus estimate of $0 .
For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Starts H2O America (HTO) at Outperform
- Kotak Upgrades Computer Age Management Services (CAMS:IN ) to Buy (1)
- RBC Capital Downgrades Coles Group Ltd. (COL:AU) (CLEGF) to Sector Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
